After 'Year of Harvest', Bayer looks to diversify modalities
Bayer Oncology's strategy has led to strong showings in small molecules and radiotherapies. Now they're on the hunt for ADCs, bispecifics, and more.
Newsletters and Deep Dive digital magazine
Bayer Oncology's strategy has led to strong showings in small molecules and radiotherapies. Now they're on the hunt for ADCs, bispecifics, and more.
Discover what clinicians can do to foster more patient-centred psychiatric care in a Q&A with neuropsychiatric physician assistant Rebecca Barbee.
January was a relatively quiet month for Board news, but there were some notable moves here and there.
As infrastructure bottlenecks ease and regulatory frameworks mature, pharma's AI adoption is shifting from proof-of-concept to production-grade deployment
Leaders must be adaptive, forward-thinking, and equipped to cultivate environments where humans and AI work together effectively and ethically.
Editor's Picks
Newsletters and Deep Dive
digital magazine